product name Nicaraven
Description: Nicaraven is a hydroxyl radical scavenger with antivasospastic and neuroprotective effects. Nicaraven causes a dose-dependent, slight inhibition of poly (ADP-ribose) synthetase activation, possibly due to a direct inhibitory effect on the catalytic activity of poly (ADP-ribose) synthetase in RAW murine macrophages stimulated with peroxynitrite. Nicaraven partially protects against the peroxynitrite-induced suppression of mitochondrial respiration in RAW macrophages and causes a slight, dose-dependent inhibition of nitrite production in RAW macrophages stimulated with bacterial lipopolysaccharide.
References: Shock. 2000 Feb;13(2):126-34; Surgery. 2000 Jun;127(6):661-9.
284.31
Formula
C15H16N4O2
CAS No.
79455-30-4
Storage
-20℃ for 3 years in powder form
-80℃ for 2 years in solvent
Solubility (In vitro)
DMSO: 57 mg/mL (200.5 mM)
Water: 57 mg/mL (200.5 mM)
Ethanol: 57 mg/mL (200.5 mM)
Solubility (In vivo)
Synonyms
other peoduct :
| In Vitro |
In vitro activity: Nicaraven causes a dose-dependent, slight inhibition of poly (ADP-ribose) synthetase activation, possibly due to a direct inhibitory effect on the catalytic activity of poly (ADP-ribose) synthetase in RAW murine macrophages stimulated with peroxynitrite. Nicaraven partially protects against the peroxynitrite-induced suppression of mitochondrial respiration in RAW macrophages and causes a slight, dose-dependent inhibition of nitrite production in RAW macrophages stimulated with bacterial lipopolysaccharide. Nicaraven (0.35 mM) significantly inhibits the maximum aggregation rate induced by adenosine diphosphate (ADP) in the healthy volunteer platelets. Nicaraven (1.75 mM) significantly reduces the maximum aggregation rate induced by collagen in platelets. Nicaraven induces dose-dependent inhibition of platelet aggregation in both healthy volunteers and patients with cerebral thrombosis. Kinase Assay: Cell Assay: |
|---|---|
| In Vivo | Nicaraven inhibits lipid peroxidation in the liver of beagle dogs, improves hepatic and systemic hemodynamics and energy metabolism, and suppresses liver enzyme release, endothelin-1 elevation in hepatic venous blood, histologic damage, and neutrophil infiltration into the liver. Nicaraven (20 mg/kg) elicits small reductions in infarction volume in male Sprague-Dawley rats subjected to transient focal ischemia. Nicaraven (60 mg/kg) provides significant reductions in the volume of infarction (18.6% and 20.9%) reductions for the pre- and posttreatment groups, respectively, in male Sprague-Dawley rats subjected to transient focal ischemia. |
| Animal model | |
| Formulation & Dosage | |
| References | Shock. 2000 Feb;13(2):126-34; Surgery. 2000 Jun;127(6):661-9. |
